Increasing prescriptions of GLP-1 RAs in adolescents These data indicate a substantial rise in AOM semaglutide, following its approval for adolescent obesity management in late 2022 ( 6 )
When used as part of a medically supervised program , patients experience many health benefits
10.3748/wjg.v20.i47.17756 13 ChenJ.WuS.WuR.AiH.LuX.WangJ.et al (2023)
Individual variation in drug response : Pharmacological responses to GLP-1 receptor agonists vary between individuals due to genetic factors, receptor sensitivity, and metabolic differences
Biological effects of a de novo designed myxoma virus peptide analogue: evaluation
[2] Wegovy slows gastric emptying, increases feelings of fullness, and reduces appetite, leading to reduced caloric intake and subsequent weight loss